However, although above results shall provide meaningful insights into better understanding of ccRCC, it’s not yet enough to classify FGF1 or other PI3K-AKT signaling proteins as new potential drug targets in ccRCC. This evidence concerns the gene FGF1 and nonpapillary renal cell carcinoma.